Impact of Guideline-Based Acute Kidney Injury Care Processes on Outcomes in Hospitalized Patients With Decompensated Cirrhosis
GOALS: We evaluated whether adherence to acute kidney injury (AKI) specific process measures (PMs) improves outcomes in hospitalized patients with cirrhosis and AKI. BACKGROUND: Expert bodies recommend PMs for the management of AKI in cirrhosis, but the link between PMs and outcomes is unclear. STUDY: We performed a retrospective cohort study of patients hospitalized with ascites and AKI at Veterans Administration hospitals. We examined the relationship between PMs [avoidance of diuretics, nonselective beta-blockers (NSBB), and other vasodilators, volume expansion with albumin/crystalloids, infectious work-up, subspecialty consultation, and postdischarge outpatient visit] and patient outcomes. Outcomes were in-hospital AKI resolution and 90-day mortality, adjusted for patient demographics, comorbidities, cirrhosis complications, Model for End-Stage Liver Disease (MELD) 3.0 score, and AKI stage. RESULTS: Among 2221 patients, adherence to PMs varied: NSBB, diuretics, and other vasodilators were avoided in 97%, 79%, and 80% of cases, respectively. Volume expansion with albumin and crystalloids was administered in 21% and 29% of cases, while 47% had an infectious workup and 29% had subspecialty consultation. Postdischarge follow-up rates within 15 days were low: 28% for primary care, 6% for gastroenterology/hepatology, and 1% for nephrology. Overall, 53% achieved AKI resolution, and 40% died within 90 days. Diuretic avoidance was associated with increased likelihood of AKI resolution (OR: 1.14, 95% CI: 1.02-1.28). Timely postdischarge outpatient visits with primary care [hazard ratio (HR): 0.53, 95% CI: 0.43-0.67] or gastroenterology/hepatology (HR: 0.44, 95% CI: 0.29-0.66) were independently associated with reduced 90-day mortality risk. CONCLUSION: Targeting specific PMs, especially diuretic avoidance and timely postdischarge outpatient visit, may improve outcomes in cirrhosis-associated AKI.
Authors
- Giuseppe Cullaro (ORCID: https://orcid.org/0000-0002-2935-0245)
- Rubén Hernáez (ORCID: https://orcid.org/0000-0002-1518-4020)
- Andrew S. Allegretti (ORCID: https://orcid.org/0000-0001-9416-6623)
- Elsa Solà (ORCID: https://orcid.org/0000-0001-6897-2760)
- Kavish Rohit Patidar (ORCID: https://orcid.org/0000-0003-3633-382X)
- George T. Cholankeril (ORCID: https://orcid.org/0000-0001-5335-8426)
- Nikhilesh R. Mazumder (ORCID: https://orcid.org/0000-0001-9749-5334)
- Jennifer R. Kramer (ORCID: https://orcid.org/0000-0003-2953-4949)
- Nagasri Shankar (ORCID: https://orcid.org/0000-0002-2225-5990)
- Prasun K. Jalal (ORCID: https://orcid.org/0000-0001-5353-2324)
- Avegail G. Flores (ORCID: https://orcid.org/0000-0002-1742-0293)
- Fasiha Kanwal (ORCID: https://orcid.org/0000-0001-6715-3966)
- Thom Taylor
- Yan Liu
Institutions
- Houston Methodist (US)
- Michael E. DeBakey VA Medical Center (US)
- Baylor College of Medicine (US)
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1097/mcg.0000000000002469
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00